News
MBIO
0.3501
-2.67%
-0.0096
Weekly Report: what happened at MBIO last week (0415-0419)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. 23andMe Holding stock moved upwards by 26.61% in the pre- market session. NRX Pharmaceuticals shares declined by 22.5% during the session.
Benzinga · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Trevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. Mustang Bio stock increased by 11.97% and SINTX Techs stock rose 10.32% in the same session. Losers TRACON Pharma and DIH Holding US stock fell by 16.6% and 14.05% respectively.
Benzinga · 04/17 20:31
Mustang Bio stock tumbles 27% amid news of mass layoffs
Mustang Bio, Inc. Stock tumbles 27% amid news of mass layoffs. The company plans to cut around 81% of its workforce to conserve cash. The layoffs are expected to be largely completed by the end of Q2. Mustang said it is cutting staff to reduce costs and preserve capital.
Seeking Alpha · 04/15 20:04
Weekly Report: what happened at MBIO last week (0408-0412)?
Weekly Report · 04/15 12:13
Mustang Bio to Cut Global Headcount by 81%
Biotechnology company Mustang Bio said it is cutting its workforce by 81% to cut costs. The company expects to book $20 million in severance-related expenses in the second quarter. Mustang Bio's stock has lost 85% of its value in the past 12 months. The biotechnology company also faces uncertainty regarding the sale of its cell processing facility.
Dow Jones · 04/12 21:25
Mustang Bio Inc Approved A Reduction Of Its Workforce By ~81% Of Its Employee Base; Workforce Reduction Will Take Place Primarily In April 2024, Expected To Be Substantially Completed In Q2 Of 2024; Continue To Evaluate All Strategic And Other Alternatives Related To Business
Benzinga · 04/12 20:21
MUSTANG BIO INC: CONTINUE TO EVALUATE ALL STRATEGIC AND OTHER ALTERNATIVES RELATED TO BUSINESS
Reuters · 04/12 20:16
Weekly Report: what happened at MBIO last week (0401-0405)?
Weekly Report · 04/08 12:19
Weekly Report: what happened at MBIO last week (0325-0329)?
Weekly Report · 04/01 12:16
Mustang Bio stock climbs 9% amid drug development update
Mustang Bio, Inc. Stock climbs 9% amid drug development update. Company plans to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. The drug candidate is currently in Phase 1/2 clinical trials for leukemia and lymphoma. Mustang was founded by Fortress Biotech (FBIO)
Seeking Alpha · 03/28 15:09
Mustang Bio Expands CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases
Planning for proof-of concept clinical trial in autoimmune diseases is underway. MB-106 CD20-targeted CAR T-cell therapy in autoimmune disease is expected to initiate in the fourth quarter of 2024. The drug is being developed to treat non-Hodgkin's lymphoma.
Benzinga · 03/28 13:03
Weekly Report: what happened at MBIO last week (0318-0322)?
Weekly Report · 03/25 12:19
Weekly Report: what happened at MBIO last week (0311-0315)?
Weekly Report · 03/18 12:17
Mustang Bio files to sell common stocks, warrants, no amount given
Mustang Bio files to sell common stocks, warrants, no amount given. This prospectus is not an offer to sell. Mustang Bio, Inc. Filed a prospectus related to the offer and sell of common stocks,. Mustang Bio (NASDAQ:MBIO) Stock.
Seeking Alpha · 03/15 21:33
Health Rounds: CAR-T therapy shows early promise against brain cancer
Health Rounds: CAR-T therapy shows early promise against brain cancer. A blood test for detecting colorectal cancer that was as accurate as current commercial home tests. Early trials hint at benefit ofCAR-T cells in glioblastoma. The therapy shrank tumors in three separate early-stage trials.
Reuters · 03/14 17:58
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Analysts have issued new ratings on iCAD, Mustang Bio and Cerus. BTIG maintained a Buy rating on the Healthcare sector with a price target of $3.00 for iCad. In a report released yesterday, BTIG also maintained a Hold rating on Cerus and a Buy on Mustang Bio.
TipRanks · 03/13 10:10
Mustang Bio GAAP EPS of -$6.00 beats by $0.67
Seeking Alpha · 03/11 20:56
Mustang Bio Reports FY23 EPS Of $(6.00) Vs $(10.09) YoY And Recent Corporate Highlights
As of December 31, 2023, Mustang's cash and cash equivalents and restricted cash totaled $7.0 million. Mustang's lead clinical candidate is MB-106, a CD20-targeted, autologous CAR T-cell therapy to treat WM and follicular lymphoma. The company announced in July 2023 that it agreed to sell its assets to uBriGene.
Benzinga · 03/11 20:24
More
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.